A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix

Gynecologic Oncology

Volumn 70, Issue 2, 1998, Pages 215-218

  Morris, Mitchell ^a   Brader, Kevin R ^a   Burke, Thomas W ^a   Levenback, Charles F ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; LEUKOCYTE COUNT; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 0032144132     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5061     Document Type: Article

References (25)

1. Omura G A. Chemotherapy for cervix cancer. Semin Oncol. 21:1994;54-62.
2. Park R C, Thigpen J T. Chemotherapy in advanced and recurrent cervical cancer. Cancer. 71:1993;1446-1450.
3. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophylotoxin-induced DNA cleavage. Cancer Res. 44:1984;5857-5860.
4. Williams S D, Birch R, Einhorn L H, Irwin L, Greco F A, Loehrer P J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 316:1987;1435-1440.
5. Einhorn L H. Initial therapy with cisplatin + VP-16 in small cell lung cancer. Semin Oncol. 13:1986;5-9.
6. Atienza D M, Vogel C L, Trock B, Swain S M. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer. 76:1995;285-2490.
7. Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol. 12:1994;60-63.
8. Grunberg S M, Felman I E, Gala K V, Johnson K B, Owens J C. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer. Am J Clin Oncol (CCT). 8:1985;393-395.
9. Waits T M, Johnson D H, Hainsworth J D, Hande K R, Thomas M, Greco F A. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol. 10:1992;292-296.
10. Slayton R E, Creasman W T, Petty W, Bundy B, Blessing J A. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Group Study. Cancer Treat Rep. 63:1979;2089-2092.
11. Slevin M L, Clark P I, Joel S P, Malik S, Osborne R J, Gregory W M, Lowe D G, Reznak R H, Wrigley P FM. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 7:1989;1333-1340.
12. Abratt R P, Willcox P A, De Groot M, Goodman H T, Jansen E R, Salton D GM. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur J Cancer. 27:1991;28-30.
13. De Jong R S, Mulder N H, Dijksterhuis D, De Vries E GE. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res. 15:1995;2319-2330.
14. Blessing J A. Design, analysis, and interpretation of chemotherapy trials in gynecologic cancer. Chemotherapy of Gynecologic Cancer. 1984;A.R. Liss, New York. p. 49-83.
15. Gehan E A. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis. 13:1961;346-353.
16. Kaplan E, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 58:1958;457-481.
17. Hainsworth J D, Johnson D H, Frazier S R, Greco F A. Chronic daily administration of oral etoposide-a phase I trial. J Clin Oncol. 7:1989;396-401.
18. Shingleton H M, Soong S J, Gelder M S, Hatch K D, Baker V V, Austin J M. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol. 73:1989;1027-1034.
19. Clark P I, Cottier B. The activity of 10-, 14-, 21-day schedules of single agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol. 19:1992;36-39.
20. Miller A A, Niell H B, Griffin J P. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer. 12:1995;59-65.
21. Robert F, Wheeler R H, Molthrop D, Bailey A, Chen S. Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. Am J Clin Oncol (CCT). 17:1994;383-386.
22. Al-Saleh E, Hoskins P J, Pike J A, Swenerton K D. Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma. Gynecol Oncol. 64:1997;468-472.
23. Hricak H, Swift P S, Campus Z, Quivey J M, Gidengorin V, Goranson H. Irradiation of the cervix uteri: value of unenhanced and contrast-enhanced MR imaging. Radiology. 189:1993;381-388.
24. Miller A A, Tolley E A, Niell H B, Griffin J P, Mauer A M. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 11:1993;1179-1188.
25. Clark P I, Slevin M L, Joel S P, Osborne R J, Talbot D I, Johnson P WM, Reznek R H, Masud T, Gregory W M, Wrigley P FM. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol. 12:1994;1427-1435.